Squamous Cell Carcinoma of the Penis Clinical Trial
Official title:
Contemporary Characteristics of Penile Carcinoma: at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, the Woodlands and Bay Area Regional Care Centers
This study develops a prospective database of patients who are evaluated and treated for penile cancer. This will facilitate analyzing trends in cancer incidence, risk factors, treatment, complications, and tumor progression. It will also prospectively validate the importance of pathological prognostic factors previously reported and outcome related to contemporary treatment.
PRIMARY OBJECTIVE: I. To prospectively collect data on the presenting features, management and outcome of penile carcinoma at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, The Woodlands and Bay Area Regional Care Centers. OUTLINE: Patients undergo data collection every 6 months for up to 15 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02104063 -
Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]
|
N/A | |
| Not yet recruiting |
NCT06161532 -
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
|
Phase 2 | |
| Completed |
NCT03517488 -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02014831 -
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)
|
Phase 2 | |
| Recruiting |
NCT03221400 -
PEN-866 in Patients With Advanced Solid Malignancies
|
Phase 1/Phase 2 |